Tumor Exosome Mimicking Nanoparticles for Tumor Combinatorial Chemo-Photothermal Therapy

Tian, Ran; Wang, Zhaosong; Niu, Ruifang; Wang, Hanjie; Guan, Weijiang; Chang, Jin

doi:10.3389/fbioe.2020.01010

Cited by 38 publications

(35 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In their research, tumor-derived exosomes were mixed with mesoporous silica nanoparticles (MSNs) loaded with DOX and ICG then exosome-camouflaged MSNs (ID@E-MSNs) was constructed through extrusion. Likewise, their outcomes demonstrated that ID@E-MSNs could produce hyperthermia to collapse nano-vehicles and accelerate drug release, achieving effective chemo-photothermal therapy under 808 nm NIR irradiation [ 70 ]. In short, all the researches above indicate that engineered EVs as delivery platforms perform strong load capacity and good biocompatibility, which means they have great potential in combinational chemo-photothermal therapy.…”

Section: Engineered Evs For Chemotherapy-related Combination Therapymentioning

confidence: 99%

Engineered extracellular vesicles: potentials in cancer combination therapy

et al. 2022

View full text Add to dashboard Cite

Extracellular vesicles (EVs) are a group of secretory vesicles with cell-derived membrane and contents. Due to the cargo delivery capability, EVs can be designed as drug delivery platforms for cancer therapy. Biocompatibility and immune compatibility endow EVs with unique advantages compared with other nanocarriers. With the development of this field, multiple ingenious modification methods have been developed to obtain engineered EVs with desired performance. Application of engineered EVs in cancer therapy has gradually shifted from monotherapy to combinational therapy to fight against heterogeneous cancer cells and complex tumor microenvironment. In addition, the strong plasticity and load capacity of engineered EV make it potential to achieve various combinations of cancer treatment methods. In this review, we summarize the existing schemes of cancer combination therapy realized by engineered EVs, highlight the mechanisms and representative examples of these schemes and provide guidance for the future application of engineered EVs to design more effective cancer combination treatment plans. Graphical Abstract

show abstract

Section: Engineered Evs For Chemotherapy-related Combination Therapymentioning

confidence: 99%

Engineered extracellular vesicles: potentials in cancer combination therapy

et al. 2022

View full text Add to dashboard Cite

show abstract

“…In agreement with the recent observation that EVs derived from autologous cancer cells have potential tropism to the TME making them competitive delivery vehicles with enhanced anticancer efficacy [ 254 ], Tian et al developed tumour-cell-derived exosome-camouflaged porous silicon nanoparticles (E-MSNs) as a drug delivery system for indocyanine (ICG) and doxorubicin (ID@E-MSNs). This approach showed synergistic effects of chemotherapy and photothermal therapy against BC [ 248 ].…”

Section: Clinical Applications Of Extracellular Vesicles In Therapy Resistancementioning

confidence: 99%

Extracellular Vesicles as Mediators of Therapy Resistance in the Breast Cancer Microenvironment

et al. 2022

View full text Add to dashboard Cite

Resistance to various therapies, including novel immunotherapies, poses a major challenge in the management of breast cancer and is the leading cause of treatment failure. Bidirectional communication between breast cancer cells and the tumour microenvironment is now known to be an important contributor to therapy resistance. Several studies have demonstrated that crosstalk with the tumour microenvironment through extracellular vesicles is an important mechanism employed by cancer cells that leads to drug resistance via changes in protein, lipid and nucleic acid cargoes. Moreover, the cargo content enables extracellular vesicles to be used as effective biomarkers for predicting response to treatments and as potential therapeutic targets. This review summarises the literature to date regarding the role of extracellular vesicles in promoting therapy resistance in breast cancer through communication with the tumour microenvironment.

show abstract

“…Table 2 summarizes different examples of NPs coated with EVs, their coating mechanisms, and the unique features of this strategy for drug delivery applications. [105,106,119,137,[146][147][148][149][150][151][152][153][154][155]…”

Section: Evs-mesoporous Silica Npsmentioning

confidence: 99%

Extracellular Vesicle Nanoarchitectonics for Novel Drug Delivery Applications

Sharma

Masud

Kaneti

et al. 2021

Small

View full text Add to dashboard Cite

Extracellular vesicles (EVs) can transfer intercellular messages in various (patho)physiological processes and transport biomolecules to recipient cells. EVs possess the capacity to evade the immune system and remain stable over long periods, identifying them as natural carriers for drugs and biologics. However, the challenges associated with EVs isolation, heterogeneity, coexistence with homologous biomolecules, and lack of site‐specific delivery, have impeded their potential. In recent years, the amalgamation of EVs with rationally engineered nanostructures has been proposed for achieving effective drug loading and site‐specific delivery. With the advancement of nanotechnology and nanoarchitectonics, different nanostructures with tunable size, shapes, and surface properties can be integrated with EVs for drug loading, target binding, efficient delivery, and therapeutics. Such integration may enable improved cellular targeting and the protection of encapsulated drugs for enhanced and specific delivery to target cells. This review summarizes the recent development of nanostructure amalgamated EVs for drug delivery, therapeutics, and real‐time monitoring of disease progression. With a specific focus on the exosomal cargo, diverse drug delivery system, and biomimetic nanostructures based on EVs for selective drug delivery, this review also chronicles the needs and challenges of EV‐based biomimetic nanostructures and provides a future outlook on the strategies posed.

show abstract

Tumor Exosome Mimicking Nanoparticles for Tumor Combinatorial Chemo-Photothermal Therapy

Cited by 38 publications

References 39 publications

Engineered extracellular vesicles: potentials in cancer combination therapy

Engineered extracellular vesicles: potentials in cancer combination therapy

Extracellular Vesicles as Mediators of Therapy Resistance in the Breast Cancer Microenvironment

Extracellular Vesicle Nanoarchitectonics for Novel Drug Delivery Applications

Contact Info

Product

Resources

About